Navigation Links
Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst,Congress of the International Society on Thrombosis and Haemostasis

SAN CARLOS, Calif., July 5 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced that data from the ANTHEM (Anticoagulation with rNAPc2 To Help Eliminate MACE)/TIMI 32 Phase 2 trial looking at recombinant nematode anticoagulant protein c2 (rNAPc2) in patients with acute coronary syndromes (ACS), preclinical data evaluating rNAPc2 in mouse models of colorectal cancer, and preclinical data evaluating the mechanism of NU172, a short-acting, direct thrombin inhibiting aptamer, will be presented at the XXIst Congress of the International Society on Thrombosis and Haemostasis (ISTH) taking place in Geneva, Switzerland, July 6-12, 2007.

The presentation details are as follows:
Date/Time: Sunday, July 8, 2007, 5:30 p.m. CEST
Poster Session (P-S-016): Tissue Factor/Factor VIIa Inhibitor Reduces
Ischemia in Patients with NSTE-ACS: Final Results of the ANTHEM-TIMI
32 Trial

Date/Time: Sunday, July 8, 2007, 5:30 p.m. CEST
Poster Session (P-S-067): Discovery of a Potent, Direct Thrombin
Inhibiting Aptamer

Date/Time: Sunday, July 8, 2007, 5:30 p.m. CEST
Poster Session (P-S-072): Pharmacokinetic/Pharmacodynamic Profile of a
Novel Aptamer Direct Thrombin Inhibitor in Cynomolgus Monkeys and
Yorkshire Pigs Following a Single IV Bolus Administration

Date/Time: Monday, July 9, 2007, 10:00 a.m. CEST
Oral Presentation (O-M-001): rNAPc2, a Novel Inhibitor of Tissue
Factor/Factor VIIa Complex, Synergizes with 5-FU or Bevacizumab in a
Mouse Model of Colorectal Cancer

Date/Time: Tuesday, July 10, 2007, 5:30 p.m. CEST
Poster Session (P-T-509): rNAPc2, a Novel Inhibitor of Tissue
Factor/Factor VIIa Complex, Suppresses Liver and Lung Metastases in Mouse
Models of Colorectal Cancer

About NuveloNuvelo, Inc. i s dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting fibrinolytic for the treatment of thrombotic-related disorders; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex that completed Phase 2 clinical development in acute coronary syndromes; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical or surgical procedures. Nuvelo is also advancing an emerging oncology pipeline, including rNAPc2 which is in Phase 2 testing for potential use as a cancer therapy, as well as NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo expects to leverage its expertise in secreted proteins and cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.

Information about Nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-517-8000.

This press release contains "forward-looking statements," which include statements regarding the timing and progress of Nuvelo's clinical stage and preclinical research programs, which statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, uncertainties relating to drug discovery; clinical development processes; enrollment rates for patien ts in our clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; the impact of competitive products and technological changes and uncertainties relating to our ability to obtain funding. These and other factors are identified and described in more detail in Nuvelo filings with the SEC, including without limitation Nuvelo's Quarterly Report on Form 10-Q for the quarter ended March 31, 2007 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements.

SOURCE Nuvelo, Inc.
-0- 07/05/2007
/CONTACT: Nicole Foderaro, Director, Corporate Communications & IR of
Nuvelo, Inc., +1-650-517-8472, nfoderaro@nuvelo.com; or Carolyn Bumgardner
Wang of WeissComm Partners, Inc., +1-415-225-5050,
carolyn@weisscommpartners.com, for Nuvelo, Inc./
/Web site: http://www.nuvelo.com /
(NUVO)



'"/>




Related medicine technology :

1. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
2. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
3. Nuvelo Announces Publication of NU206 Study Results in Gastroenterology
4. Nuvelo Announces Presentation on NU206 at 2007 American Association for Cancer Research Annual Meeting
5. Nuvelo Announces Presentation on rNAPc2 at American College of Cardiology 56th Annual Scientific Session
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... Mich. , Oct. 2, 2017 Diplomat ... 8th Day Software and Consulting, LLC , and ... 8th Day Software, based in Tennessee ... LLC. 8th Day expands EnvoyHealth,s service offerings for health ... development. "In an ...
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the ... analysis system called the HORIZON at MIBio 2017 in ... subvisible and visible particulate matter in biopharmaceutical samples with unprecedented speed ... of the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of Somerset ... of specialty vendors and unique items from across the nation, this holiday-themed event will ... services offered by the VNA. The boutique will be open Saturday, November 4 ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
Breaking Medicine News(10 mins):